吉西他滨联合顺铂治疗复发转移食管癌的疗效及安全性探讨

目的:探讨吉西他滨联合顺铂治疗复发转移食管癌的疗效及安全性。方法:吉西他滨联合顺铂治疗70例复发或转移的食管鳞癌患者，记录其近期疗效，比较不同近期疗效患者的远期疗效及不良反应。结果:吉西他滨联合顺铂治疗复发转移食管癌患者的客观缓解率为31.43%，能显著延迟治疗有效患者的无进展生存期(progression-free survival，PFS)，药物严重不良反应为血液毒性，但患者能耐受。结论:吉西他滨联合顺铂治疗复发转移食管癌具有一定的近期疗效和远期疗效，且安全可靠，值得临床推广。

Efficacy and safety of gemcitabine combined with cisplatin in the treatment of recurrent metastatic esophageal carcinoma

Objective:To study the efficacy and safety of gemcitabine combined with cisplatin in recurrent and metastatic esophageal cancer.Methods:Gemcitabine combined with cisplatin was used to treat 70 patients with esophageal squamous cell carcinoma.The short-term efficacy was recorded and the long-term efficacy and toxicity of different short-term efficacy were compared.Results:The objective remission rate of gemcitabine combined with cisplatin in the treatment of recurrent and metastatic esophageal cancer was 31.43%.Progressive-free survival(PFS) was significantly delayed in patients with effective treatment.Severe side effects of the drug were hematotoxicity and patients could tolerate it.Conclusion:Gemcitabine combined with cisplatin in the treatment of recurrent and metastatic esophageal cancer has a certain short-term and long-term efficacy,and is safe and reliable,which is worthy of clinical promotion.